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We describe a case of an adolescent male with Henoch-Schonlein purpura (HSP), presenting with cutaneous and gastrointestinal
manifestations. Endoscopy revealed diﬀuse ulcerations in the stomach, duodenum, and right colon. Biopsies revealed a
leukocytoclastic vasculitis in the skin and gastrointestinal tract. Steroid therapy led to complete resolution of the symptoms.
HSP is the most common childhood vasculitis, and is characterized by the classic tetrad of nonthrombocytopenic palpable
purpura, arthritis or arthralgias, gastrointestinal and renal involvement. It is a systemic disease where antigen-antibody (IgA)
complexes activate the alternate complement pathway, resulting in inﬂammation and small vessel vasculitis. Mild disease resolves
spontaneously, and symptomatic treatment alone is suﬃcient. Systemic steroids are recommended for moderate to severe HSP.
The prognosis depends upon the extent of renal involvement, which requires close followup. Early recognition of multiorgan
involvement, especially outside of the typical age group, as in our adolescent patient, and appropriate intervention can mitigate
the disease and limit organ damage.
1. Henoch-Schonlein Purpura
1.1. Case. A 16-year-old Hispanic male from Puerto Rico
presented with fever and sore throat for 5 days. He was
given oral penicillin by his primary care doctor. After
a day, he developed an erythematous, nonpruritic rash
which progressed proximally from both feet to thighs and
upper extremities including palms and soles. Later the feet
became swollen with moderately intense (7/10) burning
pain, aggravated by ambulation. Review of systems is unre-
markable except left ear pain. His signiﬁcant comorbidities
include asthma and gastrojejunostomy following a remote
motor vehicle accident. On physical examination, there was
pharyngeal erythema, petechiae on the soft palate, cervical
lymphadenopathy, a nodular, and nontender, nonblanching
purpuric rash involving both upper and lower extremities
with nonpitting pedal edema (Figures 1 and 2). There was
notruncalinvolvement.Twodayslater,thepatientdeveloped
abdominal pain involving the right and left upper quadrant
which was constant, colicky in nature, 8/10 in intensity,
aggravated with meals, and associated with hematemesis and
watery stools. Laboratory tests showed leukocytosis (WBC:
16,900/microL); Hb: 14g/dL; Hct: 41.2%; BUN: 16mg/dL;
Serum Creatinine: 0.9mg/dL; Urinalysis: no hematuria or
proteinuria; ESR: 58mm/Hr; CRP: 5.6mg/dL; Antistrep-
tolysinOtiter:823IU/L;C3:125mg/dL;C4:11mg/dL;ANA:
Negative;EBV-VCAIgM:Negative;Anti-HAVIgM:Negative;
HbsAg: Negative; Anti-HBc IgG: Negative; Mono spot test:
Negative; c-ANCA: 0.2 units; p-ANCA: 0.2 units; Stool for
occult blood: positive. Esophagogastroduodenoscopy (Fig-
ure 3) showed multiple erosions in the duodenum, antrum,
and the gastrojejunal anastomotic site. Histopathology (Fig-
ures 4 and 5) of the small bowel showed preserved villous
architecture, and neutrophilic and eosinophilic inﬁltrates
with leukocytoclastic vasculitis. Warthin-Starry stain was
negative for Helicobacter pylori. There was no evidence of2 Gastroenterology Research and Practice
Figure 1: Clinical picture of palpable purpura involvement of
bilateral lower extremities.
Figure 2: Clinical picture of palpable purpura involvement of
bilateral upper extremities.
epithelioid granuloma. Colonoscopy showed erythema and
inﬂammation in the terminal ileum and cecum. Cecal biopsy
also showed leukocytoclastic vasculitis. Skin biopsy (Fig-
ure 6) showed pustular leukocytoclastic ﬁbrinoid vasculitis
with microabscess. The patient was diagnosed with Henoch-
Schonlein purpura as per American College of Rheumatol-
ogy and European League Against Rheumatism (EuLAR)
and Pediatric Rheumatology Society (PReS) criteria. He was
treated with intravenous ﬂuids and kept nothing by mouth
f o r3d a y sw i t hn oe n t e r a lo rp a r e n t e r a ln u t r i t i o n .H ew a s
started on oral prednisone 20mg twice a day, with resolution
ofhissymptoms anda decreasein ESRand CRP.Hisdiet was
advanced to regular diet on the fourth hospital day.
2. Review of Literature
2.1. Introduction. Henoch-Schonlein purpura (HSP) is
a self-limited, systemic, nongranulomatous, autoimmune
complex, small vessel vasculitis, with multiorgan involve-
ment. Its etiology is unclear but is associated with infec-
tions (bacterial, viral, parasitic), medications, vaccination,
tumors (non-small cell lung cancer, prostate cancer, and
hematological malignancies), alpha-1-antitrypsin deﬁciency,
Figure 3: Endoscopic ﬁnding on EGD showing inﬂammation,
submucosal hemorrhage, and small ulceration.
Figure 4: Small bowel biopsy showing preserved villous architec-
ture.
and Familial Mediteranean Fever [1]. (Table 1). HSP is the
most common cutaneous vasculitis in children comprising
up to 90% of cases [1–3].
2.2. Epidemiology. The annual incidence varies geograph-
ically from 6.2 to 70.3 per 100,000 in children less than
17 years of age with slight male predominance (M:F =
1.2:1.0). Peak age incidence is 4–6 years and 90% of
HSP cases occur before the age of 10 years. Worldwide,
Afro-Caribbeans have the least incidence while Asians have
the highest incidence. In North America, the incidence is
13.5 per 100,000 children and Caucasians have the highest
incidence while Afro-Americans have the lowest incidence.
HSP is most commonly seen in winter and spring seasons.
In adults, the incidence varies between 3.4–14.3 per million
population. As this disease is self limited, its true incidence
may be underreported [4, 5].
2.3. Pathophysiology. Antigen and antibody complexes,
mostly IgA, form as a result of bacterial and viral infections,
vaccinations, drugs, and autoimmune mechanisms [3].
These antigen antibody complexes deposit in the small vessel
walls and activate the alternate complement pathway whichGastroenterology Research and Practice 3
Figure 5: Histopathology of HSP involvement in small bowel
showing neutrophilic and eosinophilic inﬁltrates which are seen
with karyorrhectic debris.
Figure 6: Histopathology of HSP involvement in skin showing
microabscess.
leads to neutrophil accumulation resulting in inﬂammation
and vasculitis without a granulomatous reaction. This can
involve multiple systems including skin, gastrointestinal
tract, kidney, and joints but it can involve any organ
system. Vasculitis causes extravasation of blood and its
components into the interstitial spaces resulting in edema
and hemorrhage. (Figure 7) In our case with high ASO titers,
streptococcal infection might possibly have played a role in
initiating the HSP cascade.
2.4. Clinical Features. HSP is characterized by a classic
tetrad of nonthrombocytopenic palpable purpura, arthritis
or arthralgias, gastrointestinal and renal involvement, and
rarely, other systems (lungs, central nervous system, geni-
tourinary tract) [2, 4, 6, 7]. Cutaneous involvement is the
most common presentation, although patients may present
with involvement of other organ systems.
Table 1: Etiology associations with HSP [1–3].
Bacterial: Drugs:
Group A beta hemolytic Quinolones
Streptococci
Staphylococcus aureus Clarithromycin
Helicobacter pylori Acetaminophen
Mycoplasma Codeine
Etanercept
Viral:
Hepatitis A Tumors:
Hepatitis B Non-small cell lung cancers
Hepatitis E Prostate cancer
Herpes simplex Lymphoma
Human parvovirus B19 Multiple myeloma
Varicella
Adenovirus Genetic:
CMV Alpha-1 antitrypsin deﬁciency
HIV Familial Mediteranean Fever
HLA-DRB1∗01
Vaccinations HLA-B35
MMR (mumps, measles
and rubella)
Pneumococcal Parasites:
Inﬂuenza Toxocara canis
Meningococcal
Hepatitis B
∗This list is not a comprehensive list.
2.4.1. Skin. Cutaneous manifestations include nonthrombo-
cytopenicrashwhichevolvesfromerythematoustourticarial
and macular wheels to nonblanching palpable purpura with
petechiae and ecchymoses. Palpable purpura is seen in 50%
of the cases as the presenting sign. Purpuric lesions occur
in groups and may persist up to 3–10 days. Classical HSP is
symmetrical in distribution involving dependent areas such
as the lower extremities and buttocks but it can also be seen
in the upper extremities (Figures 2 and 3). Truncal and facial
involvement can also be seen. Initially the lesions are single
and less than 1cm, but later coalesce to form ecchymotic
areas. Rarely, hemorrhagic bullae, ulcerations or dermal
scarring may be seen. On histopathology (Figures 4 and
5) leukocytoclastic vasculitis, characterized by neutrophilic
inﬁltration and prominent nuclear fragmentation, involving
the upper and middle layers of the dermis with IgA
deposition on immunoﬂuorescence, is seen. Angioedema
(nonpitting edema) can be seen in the scalp, back, and
extremities.
2.4.2. Gastrointestinal (GI). Abdominal pain (colicky in
nature, worse with food) is the most common symptom
of gastrointestinal involvement. Other symptoms include
nausea, vomiting, hematemesis, melena, and hematochezia.
These symptoms are secondary to vasculitis involving
the splanchnic circulation (mesenteric vasculitis). Rarely,
intussuception (ileoleal), ischemic necrosis of the bowel4 Gastroenterology Research and Practice
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Figure 7: Schematic diagram of HSP pathophysiology.
Table 2: Diagnostic criteria of HSP (ACR and EuLAR & PReS) [8, 9].
EuLAR/PReS criteria—2006 [3] American College of Rheumatology criteria—1990 [4]
Mandatory criterion:
(i) Palpable purpura Three or more of the following criteria are needed:
Plus at least one of the following criteria:
(1)Diﬀuse abdominal pain (1)Age 20 years or less at disease onset
(2)IgA deposition in any biopsy (2)Palpable purpura
(3)Arthritis/arthralgias (3)Acute abdominal pain with gastrointestinal bleeding
(4)Renal involvement (hematuria and/or proteinuria) (4)Biopsy showing granulocytes in the walls of small
arterioles or venules in superﬁcial layers of skin
wall, intestinal perforation, massive gastrointestinal bleed-
ing, acute acalculous cholecystitis, hemorrhagic ascites with
serositis, pancreatitis, and biliary cirrhosis may occur. Usu-
ally, skin manifestations precede gastrointestinal manifesta-
tions, but in one fourth of the cases skin lesions occur after
gastrointestinal manifestations. HSP should be considered
in the diﬀerential diagnosis of an acute abdomen (especially
in children). Endoscopic ﬁndings include erythema, edema,
petechiae, ulcers, nodular changes, hematoma-like protru-
sions, skip hyperemic ecchymotic lesions, and strictures.
These are seen in the gastric antrum, cecum, ileum, and
colon. The ulcers are small, less than 1cm2, superﬁcial,
multiple, irregular, and clean-based. The second portion of
theduodenum is most commonlyinvolved. Oncolonoscopy,
the ulcers can be as large as 2cm2, and are most common
in the rectum and ileum. The lesions in the ileum are more
severe in presentation than the other areas of involvement.
2.4.3. Joints. Joint involvement is seen in up to two-thirds
of HSP patients. In one fourth of HSP patients, this can be
the presenting sign. Typically, nonmigratory, nondestructive
polyarthralgias occur which are symmetrical in distribution
and mostly involve the knees and ankles. Joint involvement
is more commonly seen in adults than in children.
2.4.4. Renal. Hematuria (microscopic or gross) is the most
commonrenalmanifestation.Proteinuriaiseitherseenalong
with hematuria (commonly) or isolated (rarely). Most of
the cases of HSP nephritis resolve spontaneously, only 5%
progress to chronic end-stage renal disease (ESRD) at 5
years. Renal involvement is similar to IgA nephropathy
(gross hematuria and mild proteinuria following an upper
respiratory tractinfection).Persistentproteinuria andhema-
turia predict the development of ESRD. Although most of
the patients develop renal involvement within 3 monthsGastroenterology Research and Practice 5
Table 3: Treatment of HSP, indications for diﬀerent medications: [1, 10–12].
Medications Indication Comments
Acetaminophen, NSAIDs Mild rash, arthritis
Oral steroids (1-2mg/Kg)
Severe rash, cutaneous edema, severe colicky
abdominal pain, scrotal and testicular
involvement
These cannot prevent development of
systemic involvement but can be helpful for
symptomatic treatment. These decrease the
duration of symptoms when compared to
placebo group
IV steroids (1-2mg/Kg)
Same as oral steroids, should be given if
patient is not able to tolerate oral
medications
Same as oral steroids
High-dose IV pulse steroids Nephrotic range proteinuria Decreases ESRD progression (in some case
series and reports)
High-dose IV pulse steroids
plus immunosuppression
Rapidly progressive glomerulonephritis
(RPGN), hemorrhagic involvement of
lungs, brain
Grade D recommendation
Plasmapheresis and/or IV
immunoglobulin therapy
Refractory HSP to combination therapy
(steroids and immunosuppression), massive
hemorrhage in gastrointestinal or other
organs
Grade D recommendation, but evidence is
growing with multiple case series and
reports. This is used as the last resort to treat
refractory HSP.
of skin manifestations, they should be followed for a year
with urinalysis. Renal involvement is the most important
prognostic factor in determining morbidity and mortality
from HSP.
2.5. Diagnosis. HSP is a clinical diagnosis but when the
presentation is atypical, tissue biopsy may be helpful [8, 9].
Although new criteria are proposed by the European League
Against Rheumatism (EuLAR) and Pediatric Rheumatology
Society(PReS),mostofthestudiesusedoldcriteriaproposed
by American College of Rheumatology. For these criteria,
please refer to Table 2.
2.6. Diﬀerential Diagnosis. Children (less than 17 years of
age) presenting with palpable purpura and multisystem
involvement (GI, kidney and joints) without thrombocy-
topenia may be diagnosed as HSP. The diﬀerential diag-
nosis of HSP includes conditions such as Crohn’s dis-
ease, Wegener’s granulomatosis, infective endocarditis, IgA
nephropathy, and hemolytic uremic syndrome. Hypersen-
sitivity vasculitis can present as leukocytoclastic vasculitis
involving the skin (palpable purpura) and rarely, the gas-
trointestinaltract,butunlikeHSP,IgAdepositionisnotseen.
In Crohn’s disease and IgA nephropathy, there is no palpable
purpura.
2.7. Treatment. Treatment of HSP reﬂects its self-limiting
nature in 94% of children and 89% of adults. Symptomatic
treatment will be suﬃcient for symptoms such as rash and
arthritis. Acetaminophen and nonsteroidal antiinﬂamma-
tory drugs can be used [4]. Aspirin should be avoided in
children.
Oral steroids are indicated in patients with severe rash,
edema, severe colicky abdominal pain (without nausea,
vomiting), renal, scrotal, and testicular involvement. Usually
prednisone or methylprednisolone can be started at 1 to
2mg/kg per day for one to two weeks, tapering down to
0.5mg/kg/day over the next week and then 0.5mg/kg every
other day for one more week. Intravenous (IV) steroids can
be administered if the patient does not tolerate oral steroids.
Early steroid therapy decreases gastrointestinal symptoms
within 2 days compared to 12.3 days in patients without
steroids and may decrease HSP or gastrointestinal recur-
rence and reduce renal progression. Steroids may prevent
major complications such as gastrointestinal bleeding or
intussusception [10, 13–15]. High-dose IV pulse steroids
are indicated in patients with nephrotic range proteinuria
and mesenteric vasculitis. These pulse doses can range from
500mg to 1gm with various protocols leading to complete
remission of nephritis in a few studies [13]. All patients
with severe renal involvement should be referred to the
nephrologist and a renal biopsy is recommended.
Immunosuppressive drugs (cyclophosphamide, azathio-
prine, cyclosporine A, and mycophenolate mofetil) in com-
bination with high-dose IV pulse steroids are recommended
if there is no beneﬁt from steroids alone. This is usually
recommended in rapidly progressive glomerulonephritis
(RPGN) and hemorrhagic involvement of the lungs and
brain. However, not all studies can conﬁrm the beneﬁts of
treatment with steroids and immunosuppressive drugs in
preventing kidney involvement compared to placebo groups
[11, 16–18]. (Table 3)
Plasmapheresis or high-dose intravenous immunoglob-
ulin therapy may be recommended for worsening renal
function, and hemorrhage in the lungs and brain refractory
to steroids and immunosuppressive drugs. High-dose IV
pulsesteroids,immunosuppression,plasmapheresisorintra-
venous immunoglobulin therapies are grade D recomenda-
tions based on meta-analytic studies [12].
There are some case reports showing that dapsone [1]o r
colchicine [23] may be useful in chronic HSP. Since Factor6 Gastroenterology Research and Practice
Table 4: Prognostic factors for HSP: [1, 2, 19–22].
The worse prognostic factors:
(i) Greater than 8 years of age
(ii) Greater number of relapses
(iii) Higher creatinine level at the onset
(iv) Proteinuria greater than 1g/day
(v) Hematuria, anemia at diagnosis
(vi) Development of hypertension
(vii) Membranoproliferative glomerulonephritis
(viii) Fever at presentation
(ix) Purpura above the waist
(x) Persistent purpura
(xi) Elevated sedimentation rate.
(xii) Elevated IgA concentration with reduced IgM
concentration at the time of diagnosis.
(xiii) Low factor XIII level
XIII levels are found to be low in HSP patients and correlate
with the severity of gastrointestinal symptoms, Factor XIII
replacement has been advocated as an adjunctive therapy
[24].
2.8. Prognostic Factors. In general, most of the HSP cases are
self-limited, with good prognosis and ﬁve-year survival rates
of 95% [1, 2, 19–22]. One third of the patients have relapses,
which are milder and shorter in duration, usually within 4
months, and involving the same organs [1]. The prognosis
depends on the age of onset, extent of renal involvement
and its course, extent of skin involvement, particularly above
the waist line, immunoglobulin imbalance, and neurological
involvement (Table 4). In adults, a 75% survival rate seen at
14.8 years may not be solely related to intrinsic HSP, as there
may be other comorbid conditions.
2.9. Conclusion. Although HSP is uncommon in the ado-
lescent age group, non-thrombocytopenic palpable purpura
with multiorgan involvement (gastrointestinal, kidney and
joints) should make one consider the diagnosis. Prompt
diagnosis and multidisciplinary intervention can lead to
appropriate management and mitigate potential complica-
tions, as illustrated in this case.
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